Document Detail

Safety and Tolerability of Omecamtiv Mecarbil During Exercise in Patients With Ischemic Cardiomyopathy and Angina.
MedLine Citation:
PMID:  25453536     Owner:  NLM     Status:  Publisher    
OBJECTIVES: The goal of this study was to assess the safety and tolerability of omecamtiv mecarbil treatment during symptom-limited exercise in patients with ischemic cardiomyopathy and angina. These patients may have increased vulnerability to prolongation of the systolic ejection time.
BACKGROUND: Omecamtiv mecarbil is a selective cardiac myosin activator that augments cardiac contractility in patients with systolic heart failure through a dose-dependent increase in systolic ejection time.
METHODS: In this double-blind, placebo-controlled study, patients with chronic heart failure were randomized 2:1 to receive omecamtiv mecarbil or placebo in 2 sequential cohorts of escalating doses designed to achieve plasma concentrations previously shown to increase systolic function. Patients underwent 2 symptom-limited exercise treadmill tests (ETTs) at baseline (ETT1 and ETT2) and again before the end of a 20-h infusion of omecamtiv mecarbil (ETT3).
RESULTS: The primary pre-defined safety endpoint (i.e., the proportion of patients who stopped ETT3 because of angina at a stage earlier than baseline) was observed in 1 patient receiving placebo and none receiving omecamtiv mecarbil. No dose-dependent differences emerged in the proportion of patients stopping ETT3 for any reason or in the pattern of adverse events.
CONCLUSIONS: Doses of omecamtiv mecarbil producing plasma concentrations previously shown to increase systolic function were well tolerated during exercise in these study patients with ischemic cardiomyopathy and angina. There was no indication that treatment increased the likelihood of myocardial ischemia in this high-risk population. (Pharmacokinetics [PK] and Tolerability of Intravenous [IV] and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina; NCT00682565).
Barry H Greenberg; Willis Chou; Khalil G Saikali; Rafael Escandón; Jacqueline H Lee; Michael M Chen; Tatyana Treshkur; Irakli Megreladze; Scott M Wasserman; Paul Eisenberg; Fady I Malik; Andrew A Wolff; Tamaz Shaburishvili
Related Documents :
19140906 - The effects of rate-adaptive atrial pacing versus ventricular backup pacing on exercise...
11271956 - Sotalol vs metoprolol for ventricular rate control in patients with chronic atrial fibr...
9568456 - Rate adaptation of qt intervals during and after exercise in children with congenital l...
9188146 - Ciguatera fish poisoning following travel to the tropics.
12746466 - Exercise assessment of transgenic models of human cardiovascular disease.
7729436 - Differences in mechanical efficiency between power- and endurance-trained athletes whil...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-11-11
Journal Detail:
Title:  JACC. Heart failure     Volume:  -     ISSN:  2213-1787     ISO Abbreviation:  JACC Heart Fail     Publication Date:  2014 Nov 
Date Detail:
Created Date:  2014-12-2     Completed Date:  -     Revised Date:  2014-12-3    
Medline Journal Info:
Nlm Unique ID:  101598241     Medline TA:  JACC Heart Fail     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The Diastolic Pulmonary Gradient Does Not Predict Survival in Patients With Pulmonary Hypertension D...
Next Document:  Patient characteristics associated with multiple pharmacy use in the U.S. population: Findings from ...